Kerri Fitzgerald

Articles by Kerri Fitzgerald

Kerri FitzgeraldISGIO 2023 | January 23, 2024
While liver cancer is the third deadliest cancer in the world, there are still unmet needs regarding the disease.
Read More
Kerri FitzgeraldSNMMI | September 21, 2023
The approach may help inform clinical decision-making early in treatment.
Kerri FitzgeraldSNMMI | August 24, 2023
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Kerri FitzgeraldSNMMI | June 30, 2023
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
Kerri FitzgeraldOncology | September 26, 2023
A study published in the European Journal of Haematology found that a diagnosis of primary myelofibrosis (MF) or ...
Kerri FitzgeraldOsteoarthritis | May 2, 2023
In patients with an unsatisfactory response to first knee replacement, the best predictor of achieving a satisfactory ...
Kerri FitzgeraldASH Annual Meeting 2020 | August 29, 2023
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Kerri FitzgeraldASH Annual Meeting 2020 | August 29, 2023
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
Kerri FitzgeraldASH Annual Meeting 2020 | August 25, 2023
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
Kerri FitzgeraldOsteoporosis | July 3, 2023
A study published as part of the American College of Rheumatology Annual Meeting compared denosumab versus alendronate ...
Kerri FitzgeraldOncology | July 5, 2023
Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center ...
Kerri FitzgeraldCOVID-19 | July 5, 2023
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Kerri FitzgeraldOsteoporosis | August 1, 2023
Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one ...
Kerri FitzgeraldOncology | July 5, 2023
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Kerri FitzgeraldOncology | July 5, 2023
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the ...
Kerri FitzgeraldOncology | July 5, 2023
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Kerri FitzgeraldOncology | August 31, 2023
The U.S. Food and Drug Administration (FDA) approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...